Must Psilocybin Always “Assist Psychotherapy”?

This paper is a narrative, conceptual analysis drawing on historical accounts and on the authors' reading of recent clinical trials and pilot studies of serotonergic psychedelics. No explicit systematic search strategy or formal meta-analytic methods are described in the extracted text; instead, the argument is built by comparing earlier clinical traditions, trial protocols, and salient findings from representative studies (for example, pilot and controlled trials of psilocybin and larger multi-site trials such as COMP001). The authors examine procedural features reported in these trials—preparation, presence of support during drug administration, and integration sessions afterwards—and inspect how those elements have been operationalised (for instance, preparatory time ranging from about 2 to 8 hours, and typical integration comprising one or two sessions). They also consider mechanistic evidence cited in the trials, such as dose–response relationships and neuroimaging findings linking 5-HT2A receptor engagement to changes in brain connectivity, to assess whether observed clinical effects align better with a pharmacological or psychotherapeutic model. The approach is discursive rather than empirical: it synthesises trial design characteristics and selected outcome observations to argue for a particular framing of psilocybin treatment.

From their review of recent studies, Goodwin and colleagues report several empirical observations used to support their argument. Early open and controlled studies showed that relatively high doses of psilocybin produce characteristic psychedelic effects—greater connectedness, perceptual changes, and emotional re-experiencing—and that mood and anxiety effects in some trials were rapid and large on standard scales. An early pilot in treatment-resistant depression administered 10 mg and 25 mg and found the drug to be tolerable. The COMPASS Pathfinder Phase II trial (COMP001) enrolled 233 patients with treatment-resistant depression across 22 sites in 10 countries; it produced a dose–response pattern with clear separation between a 25 mg high dose and a 1 mg low dose, and 10 mg yielding intermediate effects. Because expectation and psychological support were matched across doses in that trial, the authors highlight the dose–response as consistent with a pharmacological drug effect. Regarding psychological support, the paper summarises how preparation and safeguarding are central to trial protocols: preparatory contact can range from approximately 2 to 8 hours, a responsible person must be present on dosing days, and the core supportive guidance in some trials emphasises inward attention and non-directive facilitation rather than active psychotherapeutic intervention. Integration after dosing has typically been brief—often two sessions—and in the reported trials the dose-related reduction in depressive symptoms was already evident by the day after treatment, before integration could plausibly have had an effect. The Emotional Breakthrough Inventory, a measure used in studies, predicted later reductions in depressive symptoms, suggesting that acute subjective experiences correlate with clinical improvement. By contrast, trials of MDMA for PTSD involve more prolonged therapist contact and manualised psychotherapeutic procedures, which the authors accept are appropriately described as psychotherapy assisted by a drug because the psychotherapy itself is a stand-alone evidence-based treatment delivered under the influence of the drug. The authors also flag safety and interpretability concerns: active therapist interaction during the acute psychedelic state could promote mutual unblinding, amplify demand characteristics, and carry ethical risks given patient vulnerability. They note that additional approaches combining psilocybin with evidence-based psychotherapies (for example, CBT variants used in substance use disorder trials) add many therapy hours, but that their incremental efficacy over the safety-focused support model remains unproven because necessary comparative trials have not been conducted.

Goodwin and colleagues interpret the accumulated evidence to contend that, for high-dose serotonergic psychedelics such as psilocybin, the principal therapeutic mechanism observed in the best controlled studies is the pharmacological drug effect rather than a conventional psychotherapy enhanced by a drug. They argue that the psychedelic state is largely involuntary and often incompatible with the interactive processes that define standard psychotherapies; consequently, psychological support in trials has primarily served safety and preparation rather than functioning as an evidence-based therapeutic intervention. They position these conclusions relative to historical practice and to recent trials: while low-dose psycholytic approaches historically aligned with psychotherapy, modern high-dose psychedelic protocols emphasise preparation, containment, and brief integration. The authors caution that conflating the drug effect with psychotherapy risks regulatory and conceptual confusion—regulators evaluate drugs on defined efficacy and safety, and complex therapist–patient interactions during dosing complicate causal attribution. Ethical concerns are emphasised, including the potential for therapist influence to cause unblinding, demand characteristics, or even exploitative contact during a vulnerable state; they note unregulated psychotherapy can lead to ethical violations and express concern about such harms becoming endemic if therapy is overstated as the mechanism of benefit. The paper acknowledges areas of uncertainty openly. The role of integration and the optimal content, timing, and intensity of psychological support remain inadequately studied. The authors suggest that if the post-psychedelic state does indeed increase neural plasticity, there is a plausible rationale for combining the drug with focused, evidence-based psychotherapies (for example, trauma-focused CBT) or other interventions to capitalise on a potentially receptive period—an approach they term 'psychedelic-preceded therapies'. However, they emphasise that such combinations require rigorous randomized trials to determine incremental benefit. Finally, they note that lower, subpsychedelic doses might be compatible with concurrent psychotherapy, but in that case the intervention would not, in their view, warrant the label "psychedelic-assisted psychotherapy" unless the terminology is redefined in a way they consider misleading.

The authors conclude that high-dose serotonergic psychedelic experiences produce dose-related, largely involuntary changes in consciousness that appear therapeutic for depression, but that these effects have not been demonstrated to constitute a psychotherapy as conventionally understood. Psychological support should be framed primarily as preparation and safety monitoring rather than as the active treatment mechanism. They recommend using terminology that attributes the observed effects to the drug—for example, "psilocybin treatment"—and caution against continued routine use of the phrase "psychedelic-assisted psychotherapy," which they argue could confuse regulatory assessment and impede the development of serotonergic agents at psychedelic doses. The paper calls for systematic research into the roles of integration and adjunctive psychotherapies, and for clarity about dose when considering whether simultaneous conventional psychotherapy is feasible.